Satipharm Limited, a subsidiary of Harvest One Cannabis Inc. (TSXV: HVT) ("Satipharm" or "the Company") has today announced it will sponsor a series of educational seminars, run by Medical Cannabis Research Australia (MCRA), to be held throughout the country in March. These seminars are an important source of clinical information for healthcare professionals and the talks will be by prescribers, pharmacists, patient advocates and other healthcare professionals. Logo - https://mma.prnewswire.com/media/833127/satipharm_Logo.jpg Medicinal Cannabis was legalised in Australia in November 2016. The global legal cannabis market is expected to grow to over US$20 billion by 2020. There is good clinically-trialled evidence that cannabis-based medicines may be of benefit in chronic pain, multiple sclerosis, chemotherapy-induced nausea and vomiting as well as treatment-resistant epilepsy. Jonathan Hartshorn, CEO Satipharm commented, "We are proud to support an organisation that is dedicated to the education of healthcare professionals on the use of medicinal cannabis. We know from the families in Australia that use our CBD Gelpell(R) capsules, that cannabinoids have the power to dramatically transform the quality of life in many patients who have no other therapeutic options. We hope that the education provided by this event will see more people's lives transformed using medicinal cannabis." This event continues Satipharm's commitment to support research and education around medicinal cannabis. In July 2018, Satipharm completed a phase 2 clinical study to test Satipharm's proprietary 50mg CBD Gelpell(R) capsules in paediatric patients with very severe, uncontrolled, treatment-resistant epilepsy (TRE). In this pilot study, Satipharm CBD 50mg Gelpell(R) capsules were safe for use and demonstrated a potent seizure-reducing effect among paediatric TRE patients. This result was achieved with Satipharm CBD 50mg Gelpell(R) capsules that do not contain the psychoactive cannabinoid THC. Accessing Satipharm 50mg CBD Gelpell(R) Capsules Satipharm 50mg CBD Gelpell(R) capsules are available in Australia through the Therapeutic Goods Administration (TGA) Special Access Scheme (Category B) or through the Authorised Prescriber Scheme. Patients wishing to access medicinal cannabis products should discuss access with their physician and make themselves familiar with the processes by reading the TGA advice at www.tga.gov.au Once the physician has the required approval, this prescription can then be sent to our distributor, HL Pharma, who will arrange delivery to a dispensing pharmacy. HL Pharma can be contacted at contact@hlpharma.com.au About Satipharm Satipharm is a health and wellbeing company which is specialised in the development and manufacture of cannabinoid-based products from the cannabis plant. Satipharm's focus is on delivering the highest quality products that are designed specifically with the needs of our customers in mind. Satipharm provides products of exceptional, consistent quality, that are manufactured in a regulated, safe environment in line with Good Manufacturing Practice (GMP). About MCRA The MCRA's mission is to help bring Medical Cannabis to those who need it by helping fund those researching the possibilities, educating those who can prescribe it and advocating to those who can make it available to everyone on behalf of patients everywhere. They are a Not-for-Profit Registered Australian Charity seeking to improve the quality of life of patients for whom conventional medicines have failed. Educate. Advocate. Research. https://mcra.org.au SOURCE: Satipharm Limited CONTACT: Satipharm Enquiries: Catherine Harvey, Operations Director, charvey@satipharm.com OR Media Enquiries: info@satipharm.com